We are live on ! Find out more
DMRA

Damora Therapeutics, Inc. Ordinary Shares
DMRA

65 hedge funds and large institutions have $1.45B invested in Damora Therapeutics, Inc. Ordinary Shares in 2026 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 13 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,116% more capital invested

Capital invested by funds: $65.5M → $1.45B (+$1.39B)

1,600% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 3

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

261% more funds holding

Funds holding: 18 → 65 (+47)

23.41% more ownership

Funds ownership: 69.45% → 92.86% (+23%)

Holders
65
Holders Change
+47
Holders Change %
+261.11%
% of All Funds
0.8%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.06%
New
51
Increased
13
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$226M
2
FFM
Fairmount Funds Management
Pennsylvania
+$224M
3
ACA
Avoro Capital Advisors
New York
+$97.2M
4
VA
VR Adviser
New York
+$92.6M
5
FIS
FCPM III Services
Netherlands
+$62.7M

Top Sellers

Rank Fund Capital Flow
1
JG
Jain Global
New York
-$2.77M
2
SPC
Sigma Planning Corp
Michigan
-$334K
3
SWM
SHP Wealth Management
Massachusetts
-$575
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
26
ADAR1 Capital Management
Texas
$7.23M +$7.17M +279,000 New
NCM
27
Nantahala Capital Management
Connecticut
$7.2M +$7.15M +278,000 New
Geode Capital Management
28
Geode Capital Management
Massachusetts
$6.25M +$5.9M +229,553 +1,984%
BlackRock
29
BlackRock
New York
$5.76M +$5.52M +214,917 +2,858%
VCM
30
Vanguard Capital Management
Pennsylvania
$5.23M +$5.19M +201,847 New
State Street
31
State Street
Massachusetts
$4.76M +$4.73M +183,922 New
Marshall Wace
32
Marshall Wace
United Kingdom
$4.4M +$4.36M +169,818 New
UBS Group
33
UBS Group
Switzerland
$4.15M +$3.96M +154,026 +2,411%
KCM
34
Kalehua Capital Management
Texas
$3.6M +$3.57M +139,000 New
Ameriprise
35
Ameriprise
Minnesota
$3.05M +$3.02M +117,675 New
BFM
36
Boothbay Fund Management
New York
$2.86M +$376K +14,643 +15%
SFCM
37
Seven Fleet Capital Management
California
$2.62M +$2.6M +101,248 New
Morgan Stanley
38
Morgan Stanley
New York
$2.51M +$562K +21,860 +29%
VFT
39
Vanguard Fiduciary Trust
Pennsylvania
$2.5M +$2.48M +96,664 New
Goldman Sachs
40
Goldman Sachs
New York
$2.29M +$2.27M +88,336 New
Hudson Bay Capital Management
41
Hudson Bay Capital Management
Connecticut
$1.98M +$1.96M +76,338 New
HF
42
HRT Financial
New York
$1.87M +$1.85M +72,113 New
BHCM
43
Brevan Howard Capital Management
Jersey
$1.43M +$1.42M +55,232 New
Northern Trust
44
Northern Trust
Illinois
$1.01M +$999K +38,882 New
LCM
45
Landscape Capital Management
New Jersey
$633K +$629K +24,456 New
Squarepoint
46
Squarepoint
New York
$608K +$603K +23,458 New
Barclays
47
Barclays
United Kingdom
$571K +$566K +22,034 New
CFM
48
Catalyst Funds Management
Australia
$448K +$444K +17,293 New
Bank of America
49
Bank of America
North Carolina
$405K +$371K +14,419 +1,174%
Charles Schwab
50
Charles Schwab
California
$324K +$321K +12,500 New
1
2
3

DMRA Hedge Fund Activity: Q1 2026 in Review

65 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q1 2026, worth a combined $1.45B — up 2,116% from $65.5M a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new DMRA positions and 3 closed out — a net gain of 48 holders — while 13 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $226M. The largest seller was Jain Global, exiting entirely with an estimated $2.77M sold.

  • 65 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q1 2026, up from 18 in Q4 2025.
  • Funds reported $1.45B of Damora Therapeutics, Inc. Ordinary Shares stock for Q1 2026, up 2,116% quarter-over-quarter.
  • 51 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q1 2026 and 3 closed out, a net change of +48 holders.
  • The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q1 2026 was Fidelity Investments, an estimated $226M added.
  • The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q1 2026 was Jain Global, an estimated $2.77M sold.

Based on aggregated 13F filings for Q1 2026.